Liver Diseases  >>  MK-2248  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-2248 / Merck (MSD)
NCT02161510: Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)

Completed
1
13
US
MK-2248
Merck Sharp & Dohme LLC
Hepatitis C
11/14
04/15

Download Options